The central question of type 2 diabetes (Q38162978)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on May 2013

Language	Label	Description	Also known as
English	The central question of type 2 diabetes	scientific article published on May 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

The central question of type 2 diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Thaïs Rouquet

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Marion S Bonnet

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Clément Pierre

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Michel Dallaporta

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Jean-Denis Troadec

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Julien Roux

6

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Bruno Bariohay

7

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

publication date

1 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Pharmaceutical patent analyst

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

399-427

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Globalization of diabetes: the role of diet, lifestyle, and genes

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Mechanisms linking obesity to insulin resistance and type 2 diabetes

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Intracellular organization of insulin signaling and GLUT4 translocation

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Control of glycogen deposition.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

AMP-activated protein kinase--development of the energy sensor concept.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain glucose sensing, counterregulation, and energy homeostasis

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Hypothalamic insulin signaling is required for inhibition of glucose production

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Role of brain insulin receptor in control of body weight and reproduction

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Effects of the obese gene product on body weight regulation in ob/ob mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Central nervous control of energy and glucose balance: focus on the central melanocortin system

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Identification of nesfatin-1 as a satiety molecule in the hypothalamus

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

CCK-8S activates c-Fos in a dose-dependent manner in nesfatin-1 immunoreactive neurons in the paraventricular nucleus of the hypothalamus and in the nucleus of the solitary tract of the brainstem

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Central nesfatin-1-expressing neurons are sensitive to peripheral inflammatory stimulus

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The novel function of nesfatin-1: anti-hyperglycemia

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Central NUCB2/Nesfatin-1-expressing neurones belong to the hypothalamic-brainstem circuitry activated by hypoglycaemia.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Molecular mechanisms of insulin resistance in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Insulin resistance and pancreatic beta cell failure

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage?

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Islet amyloid polypeptide, islet amyloid, and diabetes mellitus

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Hepatitis C virus infection: molecular pathways to insulin resistance

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Impact of liver diseases on the development of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Biotechnological and administration innovations in insulin therapy

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

DPP IV inhibitors: successes, failures and future prospects

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Cellular and molecular mechanisms of metformin: an overview

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Assessing the potential of glucokinase activators in diabetes therapy

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

SGLT-2 inhibitors in development for type 2 diabetes treatment

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

An update in the management of obesity: the weight of CNS targets

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin-replacement therapy for lipodystrophy.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin enters the brain by a saturable system independent of insulin

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

In vitro demonstration of a saturable transport system for leptin across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The blood-brain barrier as a cause of obesity

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Decreased blood-brain leptin transfer in an ovine model of obesity and weight loss: resolving the cause of leptin resistance

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin resistance is associated with hypothalamic leptin receptor mRNA and protein downregulation.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Region-specific leptin resistance within the hypothalamus of diet-induced obese mice.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Amylinergic control of food intake

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Mechanisms of amylin/leptin synergy in rodent models

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

It takes two to tango: combined amylin/leptin agonism as a potential approach to obesity drug development

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The role of melanocyte-stimulating hormone in insulin resistance and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The central melanocortin system directly controls peripheral lipid metabolism

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Cardiovascular responses to melanocortin 4-receptor stimulation in conscious unrestrained normotensive rats

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Weighing in the role of BDNF in the central control of eating behavior

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-Derived Neurotrophic Factor Reduces Blood Glucose Level in Obese Diabetic Mice but Not in Normal Mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-derived neurotrophic factor improves blood glucose control and alleviates fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-derived neurotrophic factor ameliorates lipid metabolism in diabetic mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The effects of brain-derived neurotrophic factor on insulin signal transduction in the liver of diabetic mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

In vivo effects of leptin-related synthetic peptides on body weight and food intake in female ob/ob mice: localization of leptin activity to domains between amino acid residues 106-140.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Epitope mapping of secreted mouse leptin utilizing peripherally administered synthetic peptides

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Intranasal delivery of mouse [D‐Leu‐4]‐OB3, a synthetic peptide amide with leptin‐like activity, improves energy balance, glycaemic control, insulin sensitivity and bone formation in leptin‐resistant C57BLK/6‐m db/db mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin-dependent control of glucose balance and locomotor activity by POMC neurons.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Leptin deficiency causes insulin resistance induced by uncontrolled diabetes

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

TrkB agonists ameliorate obesity and associated metabolic conditions in mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Appetite enhancement and weight gain by peripheral administration of TrkB agonists in non-human primates.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

G protein-coupled receptor 12 deficiency results in dyslipidemia and obesity in mice

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

A role for melanin-concentrating hormone in the central regulation of feeding behaviour

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Mice lacking melanin-concentrating hormone are hypophagic and lean

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Melanin-concentrating hormone induces insulin resistance through a mechanism independent of body weight gain

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

MCH-/- mice are resistant to aging-associated increases in body weight and insulin resistance.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Melanin concentrating hormone is a novel regulator of islet function and growth.

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.4155%2FPPA.13.22

21 January 2018

Identifiers

10.4155/PPA.13.22

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38162978&oldid=2087494236"